

Jin-Yuan Shih

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3762276/publications.pdf>

Version: 2024-02-01

179
papers

10,976
citations

44042

48
h-index

32815

100
g-index

182
all docs

182
docs citations

182
times ranked

11511
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20932-20937.	3.3	1,557
2	Management of acquired resistance to EGFR TKIâ€‘targeted therapy in advanced non-small cell lung cancer. Molecular Cancer, 2018, 17, 38.	7.9	489
3	Pretreatment Epidermal Growth Factor Receptor (<i>EGFR</i>) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Nonâ€‘Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 433-440.	0.8	471
4	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1655-1669.	5.1	418
5	Effectiveness of Tyrosine Kinase Inhibitors on â€‘Uncommonâ€‘Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Nonâ€‘Small Cell Lung Cancer. Clinical Cancer Research, 2011, 17, 3812-3821.	3.2	413
6	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncology, The, 2012, 13, 539-548.	5.1	390
7	The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell, 2006, 9, 209-223.	7.7	308
8	Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response. Clinical Cancer Research, 2008, 14, 4877-4882.	3.2	294
9	Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry. Journal of Clinical Oncology, 2017, 35, 1403-1410.	0.8	277
10	The EMT regulator slug and lung carcinogenesis. Carcinogenesis, 2011, 32, 1299-1304.	1.3	274
11	SpecificEGFRMutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Nonâ€‘Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy. Journal of Clinical Oncology, 2008, 26, 2745-2753.	0.8	249
12	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget, 2016, 7, 12404-12413.	0.8	209
13	Transcription Repressor Slug Promotes Carcinoma Invasion and Predicts Outcome of Patients with Lung Adenocarcinoma. Clinical Cancer Research, 2005, 11, 8070-8078.	3.2	201
14	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. Journal of Thoracic Oncology, 2015, 10, 793-799.	0.5	199
15	Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma. Lung Cancer, 2001, 34, 91-97.	0.9	188
16	Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. Journal of Thoracic Oncology, 2017, 12, 567-572.	0.5	188
17	EGFRMutation Conferring Primary Resistance to Gefitinib in Nonâ€‘Small-Cell Lung Cancer. New England Journal of Medicine, 2005, 353, 207-208.	13.9	166
18	Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene, 2019, 38, 455-468.	2.6	165

#	ARTICLE	IF	CITATIONS
19	Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2006, 118, 963-969.	2.3	151
20	Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1071-1079.	2.5	148
21	Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response. <i>Clinical Cancer Research</i> , 2008, 14, 162-168.	3.2	140
22	ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Cancer Letters</i> , 2013, 328, 144-151.	3.2	135
23	Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. <i>Lancet Respiratory Medicine</i> , 2018, 6, 107-116.	5.2	121
24	Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed. <i>Lung Cancer</i> , 2011, 74, 132-138.	0.9	103
25	EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR. <i>Journal of Thoracic Oncology</i> , 2012, 7, 98-104.	0.5	99
26	Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan. <i>PLoS ONE</i> , 2015, 10, e0120852.	1.1	88
27	Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report. <i>Journal of Thoracic Oncology</i> , 2011, 6, 195-198.	0.5	87
28	Survival of lung adenocarcinoma patients with malignant pleural effusion. <i>European Respiratory Journal</i> , 2013, 41, 1409-1418.	3.1	83
29	Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. <i>Lung Cancer</i> , 2011, 72, 205-212.	0.9	72
30	Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations with the Classical Mutation Pattern. <i>Oncologist</i> , 2008, 13, 1276-1284.	1.9	70
31	Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1171-1179.	0.5	70
32	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutationâ€“Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1897-1905.	0.5	68
33	First- or Second-line Therapy with Gefitinib Produces Equal Survival in Nonâ€“Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 847-853.	2.5	66
34	Percutaneous Computed Tomography-Guided Coaxial Core Biopsy for Small Pulmonary Lesions with Ground-Glass Attenuation. <i>Journal of Thoracic Oncology</i> , 2012, 7, 143-150.	0.5	65
35	Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusionâ€“Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1140-1152.	0.5	64
36	Unique <i>p53</i> and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepitheliomaâ€“like carcinomas. <i>Cancer Science</i> , 2011, 102, 282-287.	1.7	63

#	ARTICLE	IF	CITATIONS
37	Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 90430-90443.	0.8	63
38	IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. <i>Oncotarget</i> , 2015, 6, 10415-10431.	0.8	62
39	Knockdown of Contactin-1 Expression Suppresses Invasion and Metastasis of Lung Adenocarcinoma. <i>Cancer Research</i> , 2006, 66, 2553-2561.	0.4	61
40	Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. <i>Medical Oncology</i> , 2010, 27, 9-15.	1.2	61
41	Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2016, 94, 46-53.	0.9	60
42	Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C. <i>Cancer Letters</i> , 2017, 402, 190-202.	3.2	57
43	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. <i>International Journal of Cancer</i> , 2019, 144, 2887-2896.	2.3	56
44	Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. <i>European Journal of Cancer</i> , 2020, 124, 110-122.	1.3	56
45	MicroRNA in Lung Cancer Metastasis. <i>Cancers</i> , 2019, 11, 265.	1.7	55
46	Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2010, 126, 247-255.	2.3	53
47	Genetic Polymorphism of XRCC1 Arg399Gln Is Associated With Survival in Non-Small-Cell Lung Cancer Patients Treated With Gemcitabine/Platinum. <i>Journal of Thoracic Oncology</i> , 2012, 7, 973-981.	0.5	52
48	Collapsin response mediator protein-1: a novel invasion-suppressor gene. <i>Clinical and Experimental Metastasis</i> , 2003, 20, 69-76.	1.7	51
49	EGFR and p53 Status of Pulmonary Pleomorphic Carcinoma: Implications for EGFR Tyrosine Kinase Inhibitors Therapy of an Aggressive Lung Malignancy. <i>Annals of Surgical Oncology</i> , 2011, 18, 2952-2960.	0.7	51
50	Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction. <i>PLoS ONE</i> , 2011, 6, e23303.	1.1	50
51	EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. <i>Scientific Reports</i> , 2015, 5, 13574.	1.6	48
52	A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population. <i>Lung Cancer</i> , 2017, 103, 82-89.	0.9	47
53	Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. <i>Lung Cancer</i> , 2015, 88, 208-214.	0.9	46
54	Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. <i>Lung Cancer</i> , 2011, 72, 333-339.	0.9	45

#	ARTICLE	IF	CITATIONS
55	EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. <i>Lung Cancer</i> , 2009, 64, 346-351.	0.9	43
56	Clinical Significance of Thyroid Transcription Factor-1 in Advanced Lung Adenocarcinoma Under Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment. <i>Chest</i> , 2012, 141, 420-428.	0.4	42
57	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. <i>Cancer Research</i> , 2018, 78, 3350-3362.	0.4	42
58	Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. <i>Journal of Cancer</i> , 2018, 9, 1813-1820.	1.2	41
59	Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer. <i>International Journal of Cancer</i> , 2019, 145, 1609-1624.	2.3	40
60	Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2019, 20, e620-e630.	1.1	39
61	Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis. <i>Journal of Geriatric Oncology</i> , 2015, 6, 38-45.	0.5	38
62	Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6137-6145.	1.0	36
63	DUSP1 Expression Induced by HDAC1 Inhibition Mediates Gefitinib Sensitivity in Non-Small Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 428-438.	3.2	35
64	Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. <i>Lung Cancer</i> , 2013, 82, 420-425.	0.9	33
65	The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition. <i>Scientific Reports</i> , 2016, 6, 35249.	1.6	33
66	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 324-332.e1.	1.1	33
67	Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. <i>ERJ Open Research</i> , 2017, 3, 00092-2016.	1.1	33
68	Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≥ 2 cm in maximal dimension. <i>Journal of Surgical Oncology</i> , 2014, 110, 99-106.	0.8	32
69	Clinicopathologic Features and Response to Therapy of NRG1-Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021, 39, 2791-2802.	0.8	32
70	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. <i>Oncologist</i> , 2017, 22, 1075-1083.	1.9	31
71	Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. <i>European Journal of Cancer</i> , 2019, 117, 107-115.	1.3	31
72	Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. <i>Lung Cancer</i> , 2018, 120, 62-69.	0.9	29

#	ARTICLE	IF	CITATIONS
73	Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. <i>Radiotherapy and Oncology</i> , 2018, 126, 368-374.	0.3	29
74	Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. <i>Lung Cancer</i> , 2019, 133, 103-109.	0.9	29
75	Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1424-1429.	0.5	28
76	Expression of Notch Gene and Its Impact on Survival of Patients with Resectable Non-small Cell Lung Cancer. <i>Journal of Cancer</i> , 2017, 8, 1292-1300.	1.2	28
77	miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF- κ B Pathway. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 471-483.	2.3	28
78	Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-small-Cell Lung Cancer: Analysis and Literature Review. <i>Clinical Lung Cancer</i> , 2016, 17, e77-e94.	1.1	27
79	MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process. <i>Cancer Biomarkers</i> , 2020, 28, 351-363.	0.8	26
80	Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer. <i>Neoplasia</i> , 2018, 20, 838-847.	2.3	25
81	An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan. <i>Frontiers in Oncology</i> , 2020, 10, 1481.	1.3	25
82	Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. <i>European Journal of Cancer</i> , 2021, 156, 1-11.	1.3	24
83	Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. <i>European Journal of Cancer</i> , 2019, 119, 77-86.	1.3	23
84	Fucosyltransferase 4 shapes oncogenic glycoproteome to drive metastasis of lung adenocarcinoma. <i>EBioMedicine</i> , 2020, 57, 102846.	2.7	23
85	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5258-5271.	3.2	23
86	RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9000-9000.	0.8	23
87	Octogenarians with Advanced Non-small Cell Lung Cancer: Treatment Modalities, Survival, and Prognostic Factors. <i>Journal of Thoracic Oncology</i> , 2010, 5, 82-89.	0.5	22
88	The Prognostic Value of the Simplified Comorbidity Score in the Treatment of Small Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2011, 6, 378-383.	0.5	21
89	Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case. <i>Medical Oncology</i> , 2014, 31, 34.	1.2	21
90	Association of <i>BIM</i> Deletion Polymorphism With Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Adenocarcinoma. <i>JAMA Oncology</i> , 2016, 2, 826.	3.4	21

#	ARTICLE	IF	CITATIONS
91	Treating patients with <i>ALK</i> -positive non-small cell lung cancer: latest evidence and management strategy. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 274-290.	1.4	20
92	Targeting positive feedback between <i>BASP1</i> and <i>EGFR</i> as a therapeutic strategy for lung cancer progression. <i>Theranostics</i> , 2020, 10, 10925-10939.	4.6	20
93	Outcomes of cancer therapy administered to treatment-naïve lung cancer patients in the intensive care unit. <i>Journal of Cancer</i> , 2017, 8, 1995-2003.	1.2	19
94	Treatment effectiveness and tolerability of afatinib at different doses in patients with <i>EGFR</i> -mutated lung adenocarcinoma: How low can we go?. <i>European Journal of Cancer</i> , 2018, 103, 32-40.	1.3	19
95	Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of <i>EGFR</i> Inhibitors. <i>Oncologist</i> , 2019, 24, e1417-e1425.	1.9	19
96	Efficacy and Safety of Cone-Beam Computed Tomography-Derived Augmented Fluoroscopy Combined with Endobronchial Ultrasound in Peripheral Pulmonary Lesions. <i>Respiration</i> , 2021, 100, 538-546.	1.2	19
97	East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL). <i>Cancer Research and Treatment</i> , 2016, 48, 1177-1186.	1.3	19
98	Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring <i>KIF5B-RET</i> Fusion Gene. <i>Journal of Thoracic Oncology</i> , 2015, 10, e95-e96.	0.5	18
99	Clinical factors associated with treatment outcomes in <i>EGFR</i> mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. <i>BMC Cancer</i> , 2019, 19, 1006.	1.1	18
100	Validation of Immunohistochemistry for the Detection of <i>BRAF V600E</i> -Mutated Lung Adenocarcinomas. <i>Cancers</i> , 2019, 11, 866.	1.7	18
101	Vorinostat combined with brigatinib overcomes acquired resistance in <i>EGFR-C797S</i> -mutated lung cancer. <i>Cancer Letters</i> , 2021, 508, 76-91.	3.2	18
102	Complex <i>EGFR</i> mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 145, 1-9.	0.9	18
103	Prognostic factors of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma: a real-world, large cohort study. <i>Oncotarget</i> , 2018, 9, 23749-23760.	0.8	18
104	Influence of first-line chemotherapy and <i>EGFR</i> mutations on second-line gefitinib in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 67, 348-354.	0.9	17
105	Comparable clinical outcomes in patients with <i>HER2</i> mutant and <i>EGFR</i> mutant lung adenocarcinomas. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 373-381.	1.5	17
106	Best Response According to RECIST During First-line <i>EGFR</i> -TKI Treatment Predicts Survival in <i>EGFR</i> Mutation-positive Non-Small-cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2018, 19, e361-e372.	1.1	17
107	<i>IGFBP7</i> Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer. <i>Cancers</i> , 2019, 11, 36.	1.7	17
108	Ramucirumab or placebo plus erlotinib in <i>EGFR</i> -mutated, metastatic non-small cell lung cancer: East Asian subset of RELAY. <i>Cancer Science</i> , 2020, 111, 4510-4525.	1.7	17

#	ARTICLE	IF	CITATIONS
109	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. <i>Oncologist</i> , 2020, 25, 702-711.	1.9	17
110	Pleurocutaneous fistula after tube thoracostomy: Sonographic findings. <i>Journal of Clinical Ultrasound</i> , 2008, 36, 523-525.	0.4	16
111	The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094615.	1.4	15
112	Dual energy CT image prediction on primary tumor of lung cancer for nodal metastasis using deep learning. <i>Computerized Medical Imaging and Graphics</i> , 2021, 91, 101935.	3.5	15
113	The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. <i>PLoS ONE</i> , 2015, 10, e0145936.	1.1	15
114	Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib. <i>Journal of Thoracic Oncology</i> , 2015, 10, e58-e60.	0.5	14
115	The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer. <i>Scientific Reports</i> , 2018, 8, 5837.	1.6	13
116	Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. <i>Lung Cancer</i> , 2018, 118, 90-96.	0.9	13
117	Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG). <i>Oncologist</i> , 2022, 27, 255-265.	1.9	13
118	Elevated Serum Levels of Mucin-associated Antigen in Patients with Acute Respiratory Distress Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997, 156, 1453-1457.	2.5	12
119	Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 513-521.	1.5	12
120	Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers. <i>Lung Cancer</i> , 2008, 60, 92-97.	0.9	11
121	Effect of Î²-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs. <i>Frontiers in Oncology</i> , 2020, 10, 583529.	1.3	11
122	Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1. <i>Molecular Oncology</i> , 2021, 15, 560-578.	2.1	11
123	Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100140.	0.6	11
124	Real-world insights into patients with advanced NSCLC and MET alterations. <i>Lung Cancer</i> , 2021, 159, 96-106.	0.9	11
125	NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry. <i>Journal of Clinical Oncology</i> , 2019, 37, 9081-9081.	0.8	11
126	Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, e131-e140.	1.1	10

#	ARTICLE	IF	CITATIONS
127	Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain After Sequential Use of ALK Inhibitors. <i>Journal of Thoracic Oncology</i> , 2017, 12, e49-e51.	0.5	10
128	Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 326-331.	0.8	10
129	Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. <i>Cancers</i> , 2020, 12, 2658.	1.7	10
130	Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression. <i>Oncotarget</i> , 2017, 8, 61901-61916.	0.8	10
131	Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer. <i>Oncotarget</i> , 2015, 6, 12481-12492.	0.8	10
132	Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 76-82.	0.9	10
133	Significant Clinical Factors Associated with Long-term Mortality in Critical Cancer Patients Requiring Prolonged Mechanical Ventilation. <i>Scientific Reports</i> , 2017, 7, 2148.	1.6	9
134	The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 880.	1.3	9
135	Clinicopathological Features and Survival Outcomes of Primary Pulmonary Invasive Mucinous Adenocarcinoma. <i>Cancers</i> , 2021, 13, 4103.	1.7	9
136	Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 257-263.	1.1	8
137	Favorable Response to Gefitinib Treatment of Lung Adenocarcinoma With Coexisting Germline and Somatic Epidermal Growth Factor Receptor Mutations. <i>Journal of Clinical Oncology</i> , 2010, 28, e701-e703.	0.8	8
138	Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. <i>Advances in Therapy</i> , 2021, 38, 2038-2053.	1.3	8
139	Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry. <i>Journal of Clinical Oncology</i> , 2016, 34, 9014-9014.	0.8	8
140	The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer. <i>Cancers</i> , 2011, 3, 2667-2678.	1.7	7
141	Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. <i>Journal of Global Oncology</i> , 2018, 4, 1-12.	0.5	7
142	A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non-small cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor. <i>Respirology Case Reports</i> , 2019, 7, e00425.	0.3	6
143	Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel. <i>PLoS ONE</i> , 2021, 16, e0248942.	1.1	6
144	Establishing Aspergillus-Specific IgG Cut-Off Level for Chronic Pulmonary Aspergillosis Diagnosis: Multicenter Prospective Cohort Study. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 480.	1.5	6

#	ARTICLE	IF	CITATIONS
145	Multi-energy level fusion for nodal metastasis classification of primary lung tumor on dual energy CT using deep learning. <i>Computers in Biology and Medicine</i> , 2022, 141, 105185.	3.9	6
146	RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability. <i>Drug Safety</i> , 2022, 45, 45-64.	1.4	6
147	Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation. <i>Biomedicines</i> , 2021, 9, 1416.	1.4	5
148	Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1506-1513.	0.8	4
149	Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 590356.	1.3	4
150	Differences in Fatty Acid Oxidation between Nab-Paclitaxel- and Solvent-Based Paclitaxel-Treated A549 Cells Based on Metabolomics. <i>ACS Omega</i> , 2021, 6, 5138-5145.	1.6	3
151	Primary resistance to osimertinib despite acquired T790M. <i>Respirology Case Reports</i> , 2020, 8, e00532.	0.3	3
152	Not All EGFR Exon 20 Insertions Are Created Equal. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100069.	0.6	3
153	An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100292.	0.6	3
154	Trait mindfulness and depressive symptoms in non-small cell lung cancer patients: the mediating roles of quality of life and meaning in life. <i>Psychology and Health</i> , 2020, 36, 1-13.	1.2	2
155	Successful Management of a ROS1-Rearranged Pulmonary Pleomorphic Carcinoma Using Serial Tyrosine Kinase Inhibitors. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10123-10127.	1.0	2
156	Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. <i>International Journal of Clinical Oncology</i> , 2021, 26, 841-850.	1.0	2
157	A phase I dose-defining study for MK-2206 combined with gefitinib in NSCLC population enriched with EGFR mutation.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19013-e19013.	0.8	2
158	Bone-targeting agent utilization among lung cancer patients with bone metastasis in Taiwan.. <i>Journal of Clinical Oncology</i> , 2022, 40, e24111-e24111.	0.8	2
159	Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, e94-e95.	0.5	1
160	Miliary Pulmonary Nodules: An Unusual Presentation of Leptospirosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1334-1335.	2.5	1
161	Consecutive Emergence of Typical Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in a Patient With Metastatic Pulmonary Squamous Cell Carcinoma. <i>Journal of Oncology Practice</i> , 2019, 15, 115-118.	2.5	1
162	Subsequent Antituberculous Treatment may not be Mandatory among Surgically Resected Culture-Negative Pulmonary Granulomas: a Retrospective Nationwide Multicenter Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab565.	0.4	1

#	ARTICLE	IF	CITATIONS
163	The Long-Term and Mediating Effects of Mindfulness Integrated with Body-Mind-Spirit Group Therapy on Depressive Symptoms and Quality of Life Among Non-small Cell Lung Cancer Patients. <i>Mindfulness</i> , 2022, 13, 351-361.	1.6	1
164	Treatment patterns and outcomes in resectable early stage NSCLC: Interim analysis of a global real-world study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18803-e18803.	0.8	1
165	The VEGF-C/Flt-4 Axis Promotes Invasion and Metastasis of Cancer Cells. <i>Cancer Cell</i> , 2007, 11, 207.	7.7	0
166	Response to Stephane Renaud et al.. <i>Radiotherapy and Oncology</i> , 2018, 129, 188-189.	0.3	0
167	The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel with and Without Anti-angiogenic Agent in Advanced Non-small Cell Lung Cancer After Progression on Platinum-based Chemotherapy. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 1140-1150.	0.0	0
168	Time to be familiar with nontuberculous mycobacterial lung disease - An emerging disease with diverse clinical outcomes. <i>Journal of the Formosan Medical Association</i> , 2020, 119, S1-S3.	0.8	0
169	Sustained Partial Response to Afatinib in a Patient With Lung Adenocarcinoma Harboring HER2V659E Mutation. <i>JCO Precision Oncology</i> , 2020, 4, 912-915.	1.5	0
170	Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon <i>EGFR</i> mutations: A real-world cohort study (UpSwiNG).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9072-9072.	0.8	0
171	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790Mâ€™Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100099.	0.6	0
172	BIM deletion polymorphism to predict systemic treatment outcome in advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8055-8055.	0.8	0
173	Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19061-e19061.	0.8	0
174	Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after induction therapy with P/platinum for metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): A phase II multicenter randomized open-label study (GENIUS trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8043-8043.	0.8	0
175	IGFBP-7 to confer resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20572-e20572.	0.8	0
176	High Expression of FOXC1 in EGFR-TKI Resistant Non-Small Cell Lung Cancer. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-6-8.	0.0	0
177	Role of AKT3 in EGFR-TKI resistance of non-small cell lung cancer. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-6-13.	0.0	0
178	Regulation EGFR-TKI resistance by Long Noncoding RNA Clusterin in Non-Small Cell Lung Cancer. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-6-12.	0.0	0
179	Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors in NSCLC: Two Heads Are Better Than One. <i>Journal of Thoracic Oncology</i> , 2022, 17, 176-178.	0.5	0